Selectivity and Biodistribution of WVE-120101, a Potential Antisense Oligonucleotide Therapy for the Treatment of Huntingtons Disease (S56.001)

Conclusions:The stereopure ASO, WVE-120101, selectively reduced mHTT compared with wtHTT, and can access areas of the brain believed to be involved in HD.Study Supported by: WAVE Life SciencesDisclosure: Dr. Meena has received personal compensation for activities with WAVE Life Sciences as an employee. Dr. Zboray has nothing to disclose. Dr. Svrzikapa has received personal compensation for activities with WAVE Life Sciences as an employee. Dr. Mas Monteys has nothing to disclose. Dr. Mohapatra has received personal compensation for activities with WAVE Life Sciences as an employee. Dr. Lonkar has received personal compensation for activities with WAVE Life Sciences as an employee. Dr. Sokolovsk has received personal compensation for activities with WAVE Life Sciences as an employee. Dr. Yang has received personal compensation for activities with WAVE Life Sciences as an employee. Dr. Iwamoto has received personal compensation for activities with WAVE Life Sciences as an employee. Dr. Butler has received personal compensation for activities with WAVE Life Sciences as an employee. Dr. Bowman has received personal compensation for activities with WAVE Life Sciences as an employee. Dr. Standley has received personal compensation for activities with WAVE Life Sciences as an employee. Dr. Shimizu has received personal compensation for activities with WAVE Life Sciences as an employee. Dr. Frank-Kamenetsky has received personal compensation for activities with WAVE Life Sciences as ...

Source: Neurology - April 17, 2017 Category: Neurology Authors: Meena, M., Zboray, L., Svrzikapa, N., Monteys, A. M., Mohapatra, S., Lonkar, P., Sokolovsk, A., Yang, H., Iwamoto, N., Butler, D., Bowman, K., Standley, S., Shimizu, M., Frank-Kamenetsky, M., Francis, C., Davidson, B., Vargeese, C. Tags: Movement Disorders: Huntington ' s Disease and Drug-Induced Dyskinesias Source Type: research